ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 519.4 | 494.3 | 552.4 |
| Other income | 6.6 | 2.8 | 0.5 |
| Total income | 526.0 | 497.1 | 552.9 |
| Profit before exceptional items & tax | 55.4 | 28.8 | 68.3 |
| Exceptional items | -47.1 | -38.0 | 0.0 |
| Profit before tax | 8.3 | -9.2 | 68.3 |
| Net profit | 14.4 | -5.9 | 50.2 |
| Operating margin | 1.6% | -1.9% | 12.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -71.30% |
|---|---|
| Revenue, year on year | -6.00% |
NSE results filing, NSE: HIKAL. Figures extracted from the filing.
Hikal Ltd: key numbers
- Share price
- ₹224.52
- Market cap
- ₹2,768 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -553.7×Sector 43.8×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 1.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Earnings Call Transcript: Key Takeaways
Q2 revenue ₹434 Cr, EBITDA ₹45 Cr (10.3%), PAT loss ₹6 Cr. H2 recovery claimed without a quantified bridge; FY guidance reiterated despite H1 loss.
Hikal Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Hikal Results Update
Hikal Ltd reported Q2 FY27 revenue of ₹434 Crore and an EBITDA of ₹45 Crore. The company also announced the commencement of commercial production for Personal Care at its Panoli facility.
- Value
- ₹434.0 Cr
Hikal Q2 FY27 Results: Net Loss of ₹6.1 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹434.2 Cr (+36.3% YoY) and a net loss of ₹6.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹6.1 Cr
Hikal Bags New Order from Europe-based global agrochemical company
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.
- From
- Europe-based global agrochemical company (unnamed)
- Execution
- Multi-year
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.